依那西普联合甲氨蝶呤对强直性脊柱炎髋关节病变的诱导与维持治疗初步探讨

目的 初步探讨肿瘤坏死因子(TSF)-a拮抗剂对强直性脊柱炎(AS)髋关节损害的疗效,以及探讨其疗程和维持治疗的方法.方法 研究对象为AS合并髋关节损害的患者86例.治疗方案:①依那西普在开始6个月的用法为:25mg皮下注射,每周2次,持续2个月;以后每周1次再持续2个月;然后每2周1次再持续2个月.②甲氨蝶呤(MTX)15mg,口服或静脉注射,每周1次.③非甾体抗炎药(NSAIDs)和小剂量激素在控制症状后停用.结果 28例(33%)在2周内症状控制良好而停用NSAIDs;在8周内,有43例(50%)停用NSAIDs,其中36例(42%)NSAIDs和小剂量激素均已停用;在第9-16周,每周1次使用依那西普,在第16周的评价中,49例(60%)已经完全停用激素和NSAIDs;在第17-24周,每2周1次使用依那西普,有38例(44%)完全停用激素和NSAIDs,病情保持稳定.治疗后2、4、6个月髋关节功能评分均比治疗前明显提高(P<0.05);BASDAI、BASFI均下降,与治疗前对比差异均有统计学意义(P<0.05).治疗前后髋关节病变的放射学变化:治疗3个月后,19例磁共振成像(MRI)显示髋关节滑膜炎伴积液,而骨盆平片未见髋关节明显损害者中,11例滑膜炎消失,4例显著好转;骨盆平片显示有Ⅱ级或Ⅲ级损害的84个髋关节中,有13个髋关节出现放射学一个级别的改善,16个关节有改善,但未达到一个级别,49个关节没有放射学的改变.结论 依那西普与MTX联合治疗AS的髋关节损害有效,并且病情控制后,可以逐渐减低依那西普的剂量密度.

Etanercept combined with methotrexate in the induction and maintenance therapy of hip joint lesion of ankylosing spondylitis

Objective To explore the efficacy of tumor necrosis factor inhibitor in hip joint lesion of ankylosing spondylids (AS). Methods Eight-six patients with hip joint lesion of ankylosing spondylitis were Enrolled in this study. The treatment protocol was: ①Etanercept 25 mg was suncutaneously injected twice a week in the first two months and once a week in the following two months. Then it was injected once every oth-er two weeks in the last two months of the study period.②Methotrexate 15 mg was administered orally or in-travenously once a week.③NSAIDs and prednisone were stopped when symptoms sunsides. Results Twenty-eight cases (33%) stopped NSAIDs because of the disappearance of symptoms in 2 weeks after starting of the study. Forty-three (50%) stopped NSAIDs with in 8 weeks and 36 cases (42%) in them stopped NSAIDs and prednisone. During the 9th and 16th week, etanercept was used once a week and 49 cases (60%) stopped NSAIDs and prednisone. During the 17th and 24th week, etanercept was used once every two weeks, and 38 cases (44%) stopped NSAIDs and prednisone and their disease was stable. Hip Functional Scores of patients were elevated significantly at 2, 4 and 6 months after the treatment (p<0.05) BASDAI and BASFI decreased, and the difference was significant when compared to those before the treatment (P<0.05). For the 19 cases with hip joint synovitis and hydrarthrosis in MRI image but without obvious change in pelvic plain films, syn-ovitis of 11 cases disappeared and 4 cases improved significantly. In 84 hip joints with grade Ⅱ or Ⅲ changes, 13 joints improved for one grade, 16 joints had improvement but less than one grade, and 49 joints had no radiological changes. Conclusion Etanercept, when combined with methotrexate, is effective in treat-ing hip joint lesion of ankylosing spondylitis. The dosage of etanercept can be tapered after the disease is un-der control.